Evolus Inc. has presented a scientific investor presentation highlighting its advancements in aesthetics and medical biomaterials. The presentation showcases Evolysse, an innovative technology that complements the Jeuveau® brand. Evolysse demonstrates non-inferiority and statistical superiority at six months compared to Restylane-L in a pivotal trial, with significance maintained through 12 months. The company emphasizes its unique HI-PURE manufacturing process and Cold-X technology, which preserve the natural structure of the HA molecule. Symatese, the company behind this innovation, has over 25 years of experience in R&D and launched its first two products, Hemotese® and Collapat®II. The presentation also notes a strengthened R&D partnership with L'Oréal on biomaterials. You can access the full presentation through the link below.